Download this Press Release as a PDF Oxford, UK – 10th February 2025 – IngenOx Therapeutics, the Oxford-based biopharmaceutical company, announcedthat its Chief Medical Officer, Professor David Kerr CBE, met with Chinese Premier Li Qiang on 26 January 2025 at…
Oxford UK, 15 June 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that its Founding Director and Chief Medical Officer Professor David Kerr presented at the 15th Shanghai International Colorectal Cancer Symposium. Professor…
Oxford, UK, 22 May 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, participated in the China session of the 20th BioEquity Europe Conference, held in Barcelona, Spain on 20-21 May 2019. China: An R&D Hot…
Oxford 20th December 2018 – Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that CMO Professor David Kerr presented to the 3rd, World Precision Medicine (China) Summit in Shanghai. The meeting…
Oxford 21 September 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that CEO Professor Nick La Thangue presented to the Shenzhen Pingshan International Biopharmaceutical Summit on “Development Status and Trends…
These photographs were taken during David’s visit to China (May, 2018) during which he lectured at Sun Yat-sen University Cancer Hospital, Hangzhou and met with President Xu and colleagues. This was followed by his Plenary Presentation on International Colorectal Cancer…
ASH-Dec-2016-Poster-2
ASH-Dec-2016-Poster-1
ESMO-2016-Poster-1